JANX insider buying and SEC filings, explained
Janux Therapeutics, Inc. · CIK 1817713
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$347K
Planned sales (10b5-1)
$210K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jun 2, 2026 | Sale | Janeen Noel Doyle (Chief Corp. & Bus. Dev. Ofcr) sold 4,059 shares at about $14.03 ($57K). Holdings down 5% to 75,941 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 4, 2026 |
| May 11, 2026 | Sale | Maria Dobek (Vice President, Accounting) sold 2,038 shares at $14.17 ($29K). Holdings down 6% to 32,270 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| Jan 2, 2026 | Sale | Zachariah McIver (Chief Medical Officer) sold 2,714 shares at $13.73 ($37K). Holdings down 10% to 23,286 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 2, 2026 |
| Jan 2, 2026 | Sale | Maria Dobek (Vice President, Accounting) sold 1,462 shares at $13.73 ($20K). Holdings down 9% to 15,373 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 2, 2026 |
| Jan 2, 2026 | Sale | Thomas DiRaimondo (Chief Scientific Officer) sold 2,505 shares at $13.73 ($34K). Holdings down 2% to 124,425 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 2, 2026 |
| Jan 2, 2026 | Sale | Charles M. Winter (Chief Technical Officer) sold 2,401 shares at $13.73 ($33K). Holdings down 3% to 77,721 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 2, 2026 |
| Jan 2, 2026 | Sale | Andrew Hollman Meyer (Chief Business Officer) sold 1,879 shares at $13.73 ($26K). Holdings down 2% to 83,095 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 2, 2026 |
| Jan 2, 2026 | Sale | David Alan Campbell (CEO and Director) sold 8,072 shares at $13.73 ($111K). Holdings down 3% to 284,982 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 2, 2026 |
| Dec 1, 2025 | Planned (10b5-1) | Andrew Hollman Meyer (Chief Business Officer) sold 3,333 shares at about $32.98 ($110K), marked as a 10b5-1 plan trade. Holdings down 4% to 84,974 shares. | SEC filing Filed Dec 3, 2025 |
| Nov 14, 2025 | Planned (10b5-1) | Andrew Hollman Meyer (Chief Business Officer) sold 3,333 shares at $30.00 ($100K), marked as a 10b5-1 plan trade. Holdings down 4% to 84,974 shares. | SEC filing Filed Nov 14, 2025 |
18 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow JANX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.